First Time Loading...

Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 13 USD -2.69% Market Closed
Updated: May 19, 2024

Verona Pharma PLC
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Verona Pharma PLC
Interest Income Expense Peer Comparison

Comparables:
GSK
AZN
INDV
HIK
DPH

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Verona Pharma PLC
NASDAQ:VRNA
Interest Income Expense
$12.6m
CAGR 3-Years
132%
CAGR 5-Years
43%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Interest Income Expense
-£641m
CAGR 3-Years
8%
CAGR 5-Years
1%
CAGR 10-Years
0%
AstraZeneca PLC
LSE:AZN
Interest Income Expense
-$1.3B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
-12%
Indivior PLC
LSE:INDV
Interest Income Expense
$9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Interest Income Expense
-$67m
CAGR 3-Years
-27%
CAGR 5-Years
-11%
CAGR 10-Years
-6%
Dechra Pharmaceuticals PLC
LSE:DPH
Interest Income Expense
-£21m
CAGR 3-Years
-34%
CAGR 5-Years
-30%
CAGR 10-Years
-14%

See Also

What is Verona Pharma PLC's Interest Income Expense?
Interest Income Expense
12.6m USD

Based on the financial report for Dec 31, 2023, Verona Pharma PLC's Interest Income Expense amounts to 12.6m USD.

What is Verona Pharma PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
43%

The average annual Interest Income Expense growth rates for Verona Pharma PLC have been 132% over the past three years , 43% over the past five years .